Stifel Reiterates Buy Rating on Kymera Therapeutics (KYMR)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| (NASDAQ: KYMR) | Delayed: 133.14 +6.05 (4.76%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $127.09 | 52 Week High | $ | |||
| Open | $128.67 | 52 Week Low | $ | |||
| Day High | $133.21 | P/E | N/A | |||
| Day Low | $126.12 | EPS | $ | |||
| Volume | 827,427 | |||||
